Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies.
In two multicenter, double-blind studies, ciclopirox olamine cream 1% was compared with either its cream vehicle or with 1% clotrimazole cream for the treatment of patients with tinea pedis. Evaluations were made before treatment, weekly for four weeks during treatment, and for two weeks posttreatment. Ciclopirox olamine cream was significantly more effective clinically (P less than 0.001) and mycologically (P less than 0.05) than its vehicle. Ciclopirox olamine was also superior to the marketed imidazole, 1% clotrimazole cream. Significantly more patients treated with ciclopirox olamine (P less than 0.05) than those treated with clotrimazole achieved clinical and mycological cures. Both products were well tolerated.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D019301:Oleic Acid; D009829:Oleic Acids; D014677:Pharmaceutical Vehicles; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D014008:Tinea Pedis / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D009824:Ointments; D009829:Oleic Acids; D014677:Pharmaceutical Vehicles; D011728:Pyridones; D000077768:Ciclopirox; D019301:Oleic Acid